Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

Aberrant epidermal growth factor (EGF) signaling is associated with tumor growth in squamous cell carcinoma of the head and neck in humans (HNSCC), and is a major focus of targeted therapy. Cetuximab, a monoclonal antibody against EGFR, has been successful at prolonging survival but has only a 10% t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ather, Ferdows, Hamidi, Habib, Fejzo, Marlena S., Letrent, Stephen, Finn, Richard S., Kabbinavar, Fairooz, Head, Christian, Wong, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566064/
https://www.ncbi.nlm.nih.gov/pubmed/23405260
http://dx.doi.org/10.1371/journal.pone.0056112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566064/
https://www.ncbi.nlm.nih.gov/pubmed/23405260
http://dx.doi.org/10.1371/journal.pone.0056112

Ejemplares similares